VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study
Madeeva D, Christian J, Goshua G, Chun H, Lee A, Pine A. VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study. Blood 2020, 136: 34-35. PMCID: PMC8330245, DOI: 10.1182/blood-2020-142917.Peer-Reviewed Original ResearchVWF/ADAMTS13 ratioVon Willebrand factorADAMTS13 ratioVenous thrombosisNeutrophil activationCOVID-19Severe COVID-19 diseaseVWF activityNon-ICU unitsPathogenesis of coagulopathySeverity of coagulopathyAbsolute neutrophil countInstitutional review board approvalMarkers of inflammationIntensive care unitCross-sectional studyPotential therapeutic targetSodium citrate tubesReview board approvalSignificant correlationCOVID-19 diseasePossible mechanistic linkImmune system effectorsNeutrophil indexPertinent patient informationCirculating markers of angiogenesis and endotheliopathy in COVID‐19
Pine AB, Meizlish ML, Goshua G, Chang C, Zhang H, Bishai J, Bahel P, Patel A, Gbyli R, Kwan JM, Won CH, Price C, Dela Cruz CS, Halene S, van Dijk D, Hwa J, Lee AI, Chun HJ. Circulating markers of angiogenesis and endotheliopathy in COVID‐19. Pulmonary Circulation 2020, 10: 1-4. PMID: 33282193, PMCID: PMC7691906, DOI: 10.1177/2045894020966547.Peer-Reviewed Original ResearchCOVID-19 infectionMarkers of angiogenesisEndothelial injuryDisease severityCOVID-19-associated coagulopathyCritical COVID-19 infectionCOVID-19 pathogenesisCOVID-19COVID-19 diseaseEndothelial cell functionHospital mortalityMicrovascular complicationsCritical illnessElevated markersHospitalized patientsPatient populationFuture therapiesPlasma profilingSurvival analysisPatientsInfectionCell functionPotential targetInjuryMarkers